KemPharm (KMPH) Given a $9.00 Price Target at Royal Bank of Canada

KemPharm (NASDAQ:KMPH) received a $9.00 target price from equities research analysts at Royal Bank of Canada in a research report issued on Tuesday, January 16th. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank of Canada’s target price would indicate a potential upside of 56.52% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $8.35.

Shares of KemPharm (NASDAQ:KMPH) traded up $0.05 during midday trading on Tuesday, hitting $5.75. The stock had a trading volume of 64,403 shares, compared to its average volume of 120,202. KemPharm has a 52 week low of $2.45 and a 52 week high of $6.75. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56. The stock has a market capitalization of $84.28, a P/E ratio of -2.18 and a beta of -0.08.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. sell-side analysts expect that KemPharm will post -2.67 earnings per share for the current fiscal year.

In other news, EVP Daniel L. Cohen acquired 7,500 shares of the business’s stock in a transaction on Monday, November 27th. The shares were purchased at an average price of $3.79 per share, for a total transaction of $28,425.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 22.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. raised its stake in KemPharm by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after buying an additional 17,721 shares in the last quarter. C WorldWide Group Holding A S raised its stake in KemPharm by 14.1% during the third quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after buying an additional 53,829 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in KemPharm by 26.7% during the fourth quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after buying an additional 34,114 shares in the last quarter. Hedge funds and other institutional investors own 36.11% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2018/02/11/royal-bank-of-canada-analysts-give-kempharm-kmph-a-9-00-price-target.html.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply